secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tricida, Inc. (—)
CIK:        0001595585
Form:       8-K
Filed at:   2023-03-15T23:59:59+00:00
Accession:  0001595585-23-000023
Event type: m_and_a
Sentiment:  negative
Materiality: 0.85
Item codes: 2.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tricida completes sale of Veverimer to Renibus for $250K upfront + up to $152.5M milestones
--------------------------------------------------------------------------------

- Asset sale closed March 9, 2023 after Bankruptcy Court approval on Feb 22.
- Upfront cash payment of $250,000; contingent milestones tied to FDA approval and net sales up to $152.5M.
- Company remains in Chapter 11 proceedings (Case No. 23-10024).
- Veverimer (TRC101) was Tricida's lead drug candidate for chronic kidney disease.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1595585/000159558523000023/0001595585-23-000023-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1595585/000159558523000023/tcda-20230309.htm
  HTML page:      https://secwatch.observer/filing/0001595585-23-000023

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer